Abstract
Dose adjustment in obesity is particularly important for cephalosporins since these agents are widely used for surgical prophylaxis and treatment of infections. Compared with other antibiotics such as vancomycin and aminoglycosides, there is a paucity of data on the pharmacokinetics of cephalosporins in obesity and dosing recommendations are scarce. The purpose of this chapter is to review and summarise the published data to assist in developing dosing recommendations for the use of cephalosporins in obesity.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lindsay Grayson, editor. Kucers’ the use of antibiotics. 6th ed. London: Hodder Arnold; 2010.
Antibiotic Therapeutic Guidelines version 15, 2014. Melbourne, Therapeutic Guidelines (Accessed 09/10/2015). Available from: https://www.tg.org.au.
Lavollay M, Dubee V, Heym B, et al. In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus complex. Clin Microbiol Infect. 2014;20(5):297–300.
Czaja CA, Levin A, Moridani M, et al. Cefoxitin continuous infusion for lung infection caused by the mycobacterium abscessus group. Antimicrob Agents Chemo. 2014;58(6):3570–1.
Kiang TKL, Wilby KJ, Ensom MHH. A critical review on the clinical pharmacokinetics, pharmacodynamics, and clinical trials of ceftarline. Clin Pharmacokinet. 2015;54:915–31.
Rich BS, Keel R, Ho VP, Turbendian H, Afaneh CI, et al. Cefepime dosing in the morbidly patient population. Obes Surg. 2012;22(3):465–71.
Toma O, Suntrup P, Stefanescu A, et al. Pharmacokinetics and tissue penetration of cefoxitin in obesity: implications for risk of surgical site infection. Anesth Analg. 2011;113(4):730–7.
Van Kralingen S, Taks M, Diepstraten J, et al. Pharmacokinetics and protein binding of cephazolin in morbidly obese patients. Eur J Clin Pharmacol. 2011;67(10):985–92.
Hites M, Taccone FS, Wolff F, et al. Case-control study of drug monitoring of β-lactams in obese critically ill patients. Antimicrob Agents Chemother. 2013;57(2):708–15.
Janson B, Thursky K. Dsoing of antibiotics in obesity. Curr Opin Infect Dis. 2012;25:634–49.
Kiang TKL, Hafeli UP, Ensom MHH. A comprehensive review of the pharmacokinetics of antibiotics in interstitial fluid space in humans; implications on dosing and clinical pharmacokinetic monitoring. Clin Pharmacokinet. 2014;33:695–730.
Roe JL, Fuentes JM, Mullins ME. Underdosing of common antibiotics for obese patients in the ED. Am J Emerg Med. 2012;30:1212–4.
Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adults. Pharmacotherapy. 2007;27(8):1081–91.
Stitely M, Sweet M, Slain D, et al. Plasma and tissue cefazolin concentrations in obese patients undergoing Cesarean delivery and receiving differing pre-operative doses of drug. Surg Infect. 2013;14(5):455–9.
Edmiston CE, Krepel C, Kelly H, et al. Perioperative antibiotic prophylaxis in the gastric bypass patient: do we achieve therapeutic levels? Surgery. 2004;136(4):738–47.
Forse RA, Karam B, MacLean LD, Christou NV. Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery. 1989;106(4):750–6.
Payne KD, Hall RG II. Dosing of antibacterial agents in obese adults: does one size fit all? Expert Rev Infect Ther. 2014;12(1):829–54.
Ho VP, Nicolau DP, Dakin GF, et al. Cefazolin dosing for surgical prophylaxis in morbidly obese patients. Surg Infect. 2012;13(1):33–7.
Pevzner L, Swank M, Krepel C, et al. Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during Caesarian delivery. Obstet Gynecol. 2011;117(4):877–82.
Barbour A, Schmidt S, Rout WR, et al. Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery. Int J Antimicrob Agents. 2009;34(3):231–5.
Yost RI, Derendorf H. Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects. Ther Drug Monit. 1986;8(2):189–94.
Santos PD, David A, Jandourek A, et al. Ceftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience. J Chemotherapy. 2013;25(6):341–6.
Hites M, Taccone FS, Maillart E, Beurmier M, Surin R, Cotton F, Jacobs F. Broad-spectrum β-lactams in obese non-critically ill patients. Nutr Diab. 2014;4:e119.
Lovering AM, Walsh TR, Bannister GC, MacGowan AP. The penetration of ceftriaxone and cefamandole into bone, fat and haematoma and relevance of serum protein binding to their penetration into bone. J Antimicrob Chemother. 2001;47:483–6.
Satofumi I, Kinoshita H, Kawanishi T, Hayashi M. The pharmacokinetics of ceftriaxone based on population pharmacokinetics and the prediction of efficacy in Japanese adults. Eur J Drug Metab Pharmacokinet. 2009;34(2):107–15.
Georges B, Conil J, Seguin T, et al. Cefepime in intensive care unit patients: validation of a population pharmacokinetic approach and influence of covariables. Int J Clin Pharmacol Ther. 2008;46(4):157–64.
Jiang L, Shi YK, Gao W, et al. Studies of prophylactic ceftriaxone plasma concentrations in pulmonary and esophageal surgery. Chin J Antibiot. 2003;28(5):286–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Corallo, C., Zaidi, S.T.R. (2016). Cephalosporins. In: Zaidi, S., Roberts, J. (eds) Drug Dosing in Obesity. Springer, Cham. https://doi.org/10.1007/978-3-319-44034-7_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-44034-7_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-44032-3
Online ISBN: 978-3-319-44034-7
eBook Packages: MedicineMedicine (R0)